Braun Stacey Associates cut its stake in Regeneron Pharmaceuticals by 4.5% during the first quarter, lowering its holdings to ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...